Table 1.
Summary of Wnt signaling inhibitors in clinical trials.
| Name | Target/Mode of Action | Development Phase | Condition or Disease | Status | Trial Identifier |
|---|---|---|---|---|---|
| OMP-18R5 (Vantictumab) |
Anti-Fzd7 antibody | Phase I | Advanced solid tumors; metastatic breast cancer; pancreatic cancer | Completed | NCT01345201 NCT01973309 NCT02005315 NCT01957007 |
| OMP-54F28 (Ipafricept) |
Fzd8 decoy receptor | Phase I | Advanced solid tumors; ovarian cancer; hepatocellular cancer; pancreatic cancer | Completed | NCT01608867 NCT02092363 NCT02069145 NCT02050178 |
| OMP-131R10 (Rosmantuzumab) |
Anti-R-spondin3 antibody | Phase I | Advanced relapsed tumors; refractory solid tumors | Completed | NCT02482441 |
| Foxy-5 | Wnt-5a mimicking peptide | Phase II | Colon cancer | Recruiting | NCT03883802 |
| OTSA 101-DPTA | Anti Fzd10 antibody | Phase I | Relapsed or refractory synovial sarcoma | Recruiting | NCT04176016 |
| PRI-724 | Inhibitor β-catenin-CBP | Phase I/II | Advances solid tumors; chronic/acute myeloid leukemia; pancreatic cancer | Terminated or Completed | NCT01302405 NCT01606579 NCT01764477 |
| CWP291 | Sam68 | Phase I | Acute/chronic myeloid leukemia | Completed | NCT01398462 |
| SM08502 | CLK | Phase I | Advanced solid tumors | Recruiting | NCT03355066 |
| Wnt974 (LGK974) | Porcupine inhibitor | Phase I | Advanced solid tumors | Recruiting | NCT01351103 |
| ETC-159 | Porcupine inhibitor | Phase I | Advanced solid tumors | Recruiting | NCT02521844 |
| RXC004 | Porcupine inhibitor | Phase I | Advanced solid tumors | Recruiting | NCT03447470 |
| CGX1321 | Porcupine inhibitor | Phase I | Advanced GI tumors | Recruiting | NCT02675946 |
Fzd, frizzled; CBP, CREB binding protein; CLK, CDC-like kinase; GI, gastrointestinal.